Last Updated: August 5, 2026

Details for Patent: 11,033,499

Name: Drug Patent Intelligence for US Patent 11033499
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,033,499 protect, and when does it expire?

Patent 11,033,499 protects OZEMPIC, RYBELSUS, and WEGOVY, and is included in two NDAs.

This patent has seven patent family members in five countries.

Summary for Patent: 11,033,499

Title:	Tablet formulation comprising a GLP-1 peptide and a delivery agent
Abstract:	The present invention relates to solid compositions comprising a GLP-1 peptide and a delivery agent, such as SNAC, as well as uses thereof.
Inventor(s):	Simon Bjerregaard Jensen, Per Sauerberg, Flemming S. Nielsen, Betty L. Pedersen, Erik Skibsted
Assignee:	Novo Nordisk AS
Application Number:	US15/958,236
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 11,033,499

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novo	OZEMPIC	semaglutide	TABLET;ORAL	213051-004	Dec 9, 2024		RX	Yes	Yes	11,033,499	⤷ Start Trial	Y			METHOD OF TREATING TYPE 2 DIABETES MELLITUS	⤷ Start Trial
Novo	OZEMPIC	semaglutide	TABLET;ORAL	213051-005	Dec 9, 2024		RX	Yes	Yes	11,033,499	⤷ Start Trial	Y			METHOD OF TREATING TYPE 2 DIABETES MELLITUS	⤷ Start Trial
Novo	OZEMPIC	semaglutide	TABLET;ORAL	213051-006	Dec 9, 2024		RX	Yes	Yes	11,033,499	⤷ Start Trial	Y			METHOD OF TREATING TYPE 2 DIABETES MELLITUS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,033,499

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
China	104487056	⤷ Start Trial
European Patent Office	2863895	⤷ Start Trial
Spain	2871328	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.